Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial

Study limitation reported by the research below: “Trial was stopped early (166 of 168 planned patients enrolled) after FDA approval of adjuvant alectinib; the study may be underpowered to detect a smaller true effect.”